Search - tctmd.com

Displaying 261 - 280 of 549

Sort: Relevancy | Date

News Conference News EuroPCR 2016

Studies Highlight Permanent Pacemaker Rates Among New-Generation TAVR Devices

Michael O'Riordan

May 23, 2016

News Conference News EuroPCR 2016

Valvular Interventions for the Asymptomatic and Low Risk: Coming Soon to a Cath Lab Near You?

Yael L. Maxwell

May 20, 2016

News Industry News

Edwards SAPIEN 3 Transcatheter Valve Demonstrates Positive Patient Outcomes At 30 Days In European Real-World Experience

May 17, 2016

News Conference News EuroPCR 2016

‘Signal’ of Poor Durability Seen With First-Generation TAVR Devices

Caitlin E. Cox

May 17, 2016

News Daily News

Italian Registry Cautions Against TAVR in Low-Risk Patients

L.A. McKeown

May 16, 2016

News Daily News

¿Predilatación o No Predilatación en TAVR? Una Serie Europea Tranquiliza en Ambos Sentidos

Michael O'Riordan

May 02, 2016

News Daily News

TAVR 是否需要预扩张？欧洲系列研究对两者都提供支持

Michael O'Riordan

May 02, 2016

News Daily News

Predilatation or No Predilatation in TAVR? European Series Offers Reassurances Both Ways

Michael O'Riordan

May 02, 2016

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for April 2016

Shelley Wood

April 29, 2016

News Daily News

研究支持特定患者 TAVR 后可不收治 ICU

Todd Neale

April 27, 2016

News Daily News

Un Estudio Avala que es Seguro Proceder a la UCI Post-TAVR en Pacientes Seleccionados

Todd Neale

April 27, 2016

News Daily News

Study Supports Safety of Forgoing ICU Stay After TAVR in Selected Patients

Todd Neale

April 27, 2016

News Daily News

La FA Post-TAVR se Asocia a un Mayor Riesgo de Mortalidad y Hemorragias

Michael O'Riordan

April 18, 2016

News Daily News

房颤 TAVR 后相关死亡和出血风险增加

Michael O'Riordan

April 18, 2016

News Daily News

A-fib Post-TAVR Associated With Increased Risk of Mortality, Bleeding

Michael O'Riordan

April 18, 2016

News Opinion Editor's Corner ACC 2016

Hot or Not, This Year’s Trials Offer Food for Thought: My Takeaways From ACC 2016

Shelley Wood

April 13, 2016

News Conference News ACC 2016

Valve Hemodynamic Deterioration Post-TAVR Is Rare, Not Linked With Adverse Cardiovascular Outcomes

Michael O'Riordan

April 07, 2016

News Conference News ACC 2016

Self-Expanding Transcatheter Valve Maintains Advantage Over Surgery at 3 Years in High-Risk Elderly Patients

L.A. McKeown

April 04, 2016

News Conference News ACC 2016

TAVR Mortality Declines as Volumes Increase: So How Many US Centers Are Enough?

Shelley Wood

April 03, 2016

News Conference News ACC 2016

Sapien 3 Superior to Surgery Among Intermediate-Risk Patients in Observational Trial

Yael L. Maxwell

April 03, 2016

Advertisement

Studies Highlight Permanent Pacemaker Rates Among New-Generation TAVR Devices

Valvular Interventions for the Asymptomatic and Low Risk: Coming Soon to a Cath Lab Near You?

Edwards SAPIEN 3 Transcatheter Valve Demonstrates Positive Patient Outcomes At 30 Days In European Real-World Experience

‘Signal’ of Poor Durability Seen With First-Generation TAVR Devices

Italian Registry Cautions Against TAVR in Low-Risk Patients

¿Predilatación o No Predilatación en TAVR? Una Serie Europea Tranquiliza en Ambos Sentidos

TAVR 是否需要预扩张？欧洲系列研究对两者都提供支持

Predilatation or No Predilatation in TAVR? European Series Offers Reassurances Both Ways

TCTMD’s Top 10 Most Popular Stories for April 2016

研究支持特定患者 TAVR 后可不收治 ICU

Un Estudio Avala que es Seguro Proceder a la UCI Post-TAVR en Pacientes Seleccionados

Study Supports Safety of Forgoing ICU Stay After TAVR in Selected Patients

La FA Post-TAVR se Asocia a un Mayor Riesgo de Mortalidad y Hemorragias

房颤 TAVR 后相关死亡和出血风险增加

A-fib Post-TAVR Associated With Increased Risk of Mortality, Bleeding

Hot or Not, This Year’s Trials Offer Food for Thought: My Takeaways From ACC 2016

Valve Hemodynamic Deterioration Post-TAVR Is Rare, Not Linked With Adverse Cardiovascular Outcomes

Self-Expanding Transcatheter Valve Maintains Advantage Over Surgery at 3 Years in High-Risk Elderly Patients

TAVR Mortality Declines as Volumes Increase: So How Many US Centers Are Enough?

Sapien 3 Superior to Surgery Among Intermediate-Risk Patients in Observational Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content